Heparin-Induced Thrombocytopenia

Heparin-induced thrombocytopenia (HIT) is a paradoxical, immune-mediated prothrombotic disorder characterized by thrombocytopenia and thrombosis that develops during or shortly after exposure to heparin therapy. It represents one of the most important iatrogenic causes of thrombosis in hospitalized patients and carries significant morbidity and mortality if unrecognized. HIT occurs in approximately 0.1-5% of patients receiving unfractionated heparin (UFH) and 0.1-1% receiving low-molecular-weight heparin (LMWH), with higher incidence in cardiac surgery and orthopedic populations. The distinction between Type I HIT (benign, platelet count nadir >100,000/μL within 1-2 days) and Type II HIT (immune-mediated, described in detail below) is clinically critical. Understanding HIT pathophysiology and diagnosis is essential for Step 2 CK as it tests both clinical recognition and knowledge of alternative anticoagulation strategies.

HIT is a quintessential example of immune-mediated drug toxicity with paradoxical prothrombotic consequences. The disease process involves multiple sequential steps linking heparin exposure to both thrombocytopenia and thrombosis.

Heparin molecules bind to platelet factor 4 (PF4), a small positively charged chemokine normally released from platelet α-granules during aggregation or cell activation. The binding of heparin to PF4 creates a new conformational epitope recognized as foreign by the immune system. In susceptible individuals, this PF4-heparin complex activates B cells, leading to production of IgG antibodies (occasionally IgM or IgA) specifically targeting epitopes on the PF4-heparin complex. This process of immunization typically requires 5-7 days of exposure, explaining why HIT rarely occurs within the first 24 hours except in patients with recent prior heparin exposure (who have pre-existing antibodies). The molecular basis for susceptibility remains incompletely understood but appears related to both genetic (HLA associations) and acquired immune factors. UFH produces higher antibody titers than LMWH due to its longer length and greater ability to bridge multiple PF4 molecules, though LMWH can still cause HIT due to cross-reactivity.

Once circulating anti-PF4-heparin IgG antibodies form, they bind to the Fc gamma IIa receptors (FcγIIa) on platelet surfaces in a bivalent or multivalent manner, creating immune complexes. This cross-linking of FcγIIa receptors on adjacent platelets triggers intracellular signaling cascades involving Lyn and Syk tyrosine kinases, leading to calcium mobilization and platelet activation. Activated platelets undergo morphologic changes, aggregate, and release their granule contents including additional PF4, thrombin, and other prothrombotic substances. This creates a vicious cycle: newly released PF4 binds heparin in the circulation, forming additional antigenic complexes that become targets for antibody binding, driving further platelet activation and aggregation. The procoagulant phosphatidylserine externalization on platelet surfaces and release of microparticles contribute to the intense prothrombotic state. Notably, platelet activation occurs specifically in the presence of UFH or LMWH—without heparin present, the antibodies do not cause platelet activation, which is why heparin is required for both disease induction and perpetuation. This functional antibody activity (detected by platelet activation assays) rather than simple antibody presence defines clinically significant HIT.

Activated platelets generate thrombin through exposure of tissue factor (TF) on microparticles and through contact pathway activation. Multiple prothrombotic mechanisms are simultaneously activated: platelet-derived microparticles express phosphatidylserine and tissue factor, providing catalytic surfaces for thrombin generation; PF4 released from granules binds heparin and neutralizes its anticoagulant effects in localized microenvironments; and endothelial dysfunction occurs partly through antibody-mediated complement activation and direct endothelial injury. The result is simultaneous consumption of platelets (causing thrombocytopenia) and generation of thrombin (causing thrombosis), producing the pathognomonic combination of low platelets with high thrombotic risk. The paradox of HIT—that a patient is both thrombocytopenic AND hypercoagulable—reflects consumption of platelets while simultaneously generating thrombotic activity in situ. Thrombin amplification can be enormous, and systemic levels of thrombin-antithrombin complexes and D-dimer are typically markedly elevated, reflecting intense thrombin generation.

Beyond platelet effects, HIT antibodies directly activate endothelial cells through cross-linking of endothelial Fc receptors and complement deposition, particularly via C5a generation. This endothelial activation increases tissue factor expression, promotes leukocyte recruitment, and increases vascular permeability. The endothelial surface normally maintains anticoagulant properties through thrombomodulin and heparan sulfate expression; HIT-related endothelial dysfunction impairs these protective mechanisms. This explains why HIT can lead to microvascular thrombosis affecting multiple organs, including skin (leading to thrombotic complications at injection sites), limbs, and internal organs. The inflammation driven by complement activation (particularly C5a and C5b-9 deposition) perpetuates the thrombotic state and explains the clinical severity of HIT relative to antibody levels alone.

UFH is the most common cause of clinically significant HIT, with incidence of 0.1-5% depending on patient population and heparin source. The higher risk with UFH versus LMWH relates to UFH's greater binding avidity to PF4 (due to longer mean chain length of ~15,000 Daltons and higher charge density), creating stronger immunogenic complexes. UFH is used across multiple settings: cardiac surgery and cardiopulmonary bypass (where HIT incidence approaches 5%), acute coronary syndrome with percutaneous intervention, venous thromboembolism treatment, and hemodialysis. Post-operative cardiac surgery patients have dramatically elevated HIT risk, possibly due to increased PF4 release from platelet activation during bypass and heightened immune activation from surgical trauma.

LMWH causes HIT in 0.1-1% of exposed patients, roughly one-tenth the rate of UFH. Although LMWH chains are shorter (~5,000 Daltons) and bind less avidly to PF4, cross-reactivity of anti-PF4-UFH antibodies with PF4-LMWH complexes occurs in approximately 80-90% of patients with HIT antibodies. This cross-reactivity is clinically important: patients with documented HIT from UFH cannot be switched to LMWH (despite its lower HIT risk with primary exposure) because existing antibodies will cause recurrent HIT. LMWH-induced HIT may present later than UFH-induced HIT (median onset day 8-9 versus day 5-6), though delayed-onset HIT beyond 30 days can occur with either agent.

Fondaparinux, a selective factor Xa inhibitor used for thromboprophylaxis and VTE treatment, causes HIT in rare cases, estimated at less than 0.1% of exposed patients. Most HIT cases attributed to fondaparinux occur in patients with prior heparin exposure, suggesting fondaparinux can cause HIT in those already sensitized to heparin. Cross-reactivity exists but is less common than with LMWH.

Age over 40 years confers increased HIT risk, as does female sex in some studies. Orthopedic surgery (particularly hip and knee replacement), cardiac surgery, and acute coronary syndrome patients have markedly elevated risk. Medical patients (without surgery) have lower HIT risk than surgical patients. Severity of underlying illness, use of multiple medications, and immune activation from infection or inflammation may increase susceptibility. Patients with prior heparin exposure within the past 100 days have dramatically increased HIT risk due to pre-existing antibodies, potentially developing rapid-onset HIT (within 24 hours of re-exposure). Heparin source may matter—some preparations have higher immunogenicity, though this is debated.

Counter-intuitively, therapeutic-dose heparin carries lower HIT risk than prophylactic-dose heparin in some series, possibly because therapeutic doses rapidly induce anticoagulation that may mitigate thrombotic complications. However, this does not negate the absolute higher incidence in cardiac surgery and orthopedic patients despite varying dosing strategies.

HIT presents with a characteristic temporal pattern and constellation of findings that distinguish it from other causes of thrombocytopenia in hospitalized patients.

The classic presentation is platelet count decline beginning 5-7 days after initiation of heparin therapy, or within 24 hours if the patient has recent prior heparin exposure. Platelet count typically falls from baseline by ≥50% and often reaches nadirs in the range of 20,000-100,000/μL, though counts can fall lower. The decline is absolute (not relative), and the nadir usually occurs 7-10 days after heparin initiation. In delayed-onset HIT (uncommon but important), thrombocytopenia develops days to weeks after heparin has been discontinued, reflecting continued antibody effects after heparin clearance.

Most patients with HIT develop thrombosis (termed HIT with thrombosis, or HITT): approximately 50% develop new thrombotic events if HIT is not recognized and heparin not discontinued. Venous thrombosis predominates, with deep vein thrombosis (DVT) of the lower extremities most common, followed by upper extremity DVT, pulmonary embolism, and thrombosis at the site of central venous catheters. Arterial thrombosis, though less frequent, is highly specific for HIT and includes limb-threatening arterial occlusions, myocardial infarction, and stroke. Thrombosis can occur at unusual sites: adrenal vein thrombosis (causing acute adrenal insufficiency), mesenteric thrombosis (causing ischemic bowel), and cerebral venous sinus thrombosis. The appearance of new thrombosis coinciding with platelet count decline is a major diagnostic clue.

Localized erythema, induration, and necrosis at heparin injection sites occur in 10-15% of HIT patients, representing thrombotic complications within dermal and subcutaneous vessels. This presents as a red, indurated, sometimes painful lesion at an injection site, appearing typically 5-10 days after heparin initiation, often before systemic thrombosis becomes evident. Skin necrosis is uncommon but highly specific for HIT.

Fever develops in approximately 10-15% of HIT cases, reflecting the inflammatory nature of the disease and immune activation. Chills, malaise, and constitutional symptoms may accompany HIT presentation. Tachycardia and other hemodynamic changes reflect both thrombotic complications and systemic inflammation.

Stroke or transient ischemic attack from arterial or venous thrombosis can be the presenting sign of HIT. Cognitive changes or altered mental status may reflect hypercoagulability and microvascular thrombosis.

Dyspnea and hypoxemia may reflect pulmonary embolism (occurring in 10-15% of HITT patients). Chest pain suggests either PE or acute coronary syndrome from arterial thrombosis. Acute right heart strain or hemodynamic instability from massive PE represents a life-threatening HIT complication.

A crucial distinguishing feature: despite significant thrombocytopenia, bleeding is uncommon in HIT (distinguishing it from immune thrombocytopenia, sepsis-associated DIC, or dilutional thrombocytopenia). The absence of mucosal bleeding, petechiae, or spontaneous hemorrhage despite platelet counts of 20,000-40,000/μL is a red flag that the thrombocytopenia is HIT rather than other causes, since functioning platelets are present and being consumed in thrombosis rather than lost to bleeding.

Diagnosis of HIT requires a combination of clinical suspicion, laboratory testing, and integration of both clinical and immunologic findings. The 4Ts scoring system provides a standardized approach to pre-test probability.

This system combines four clinical features to stratify HIT probability before serologic testing:

Thrombocytopenia: Two points if platelet count nadir ≥50,000/μL OR >50% decline; one point if 30,000-50,000 or 30-50% decline; zero points if <30,000 or <30% decline

Timing of platelet decline: Two points if day 5-10 OR day 1-2 with prior heparin exposure; one point if day >10 OR day 1-2 without heparin exposure; zero points if <day 1

Thrombosis or other skin manifestations: Two points if new thrombosis, skin necrosis at injection site, or acute systemic reaction; one point if progressive thrombosis, recurrent thrombosis, or erythematous skin reaction; zero points if no thrombosis or skin findings

Other cause of thrombocytopenia (differential diagnosis): Two points if none apparent; one point if possible other causes; zero points if defintely another cause

Scores ≥6 indicate high probability (>80%) of HIT; 4-5 indicate intermediate probability (20-80%); ≤3 indicate low probability (<5%). This score guides the need for and interpretation of further testing. Notably, 4Ts score has ~80% negative predictive value, meaning HIT is unlikely if score is low AND serologic tests are negative.

Two main categories of tests detect anti-PF4-heparin antibodies:

ELISA (enzyme-linked immunosorbent assay): Most commonly used first-line test. Detects IgG, IgM, and IgA antibodies binding to PF4-heparin complex. Sensitivity 85-98%, but specificity only 85-90%, meaning many patients have antibodies without clinical HIT (seroconversion occurs in 15-30% of heparin-exposed patients). ELISA is rapid (results in hours) and widely available, but positive ELISA does not equal HIT diagnosis—clinical correlation is essential. ELISA results are reported semiquantitatively (low, medium, high titer); higher titers correlate better with clinically significant HIT.

HIA (heparin-induced aggregation test) and other functional assays: Including the serotonin release assay (SRA) and platelet aggregometry. These detect functionally significant antibodies that activate platelets in the presence of heparin. SRA is considered the gold standard test for HIT, with high specificity (>95%) and sensitivity (85-95%), detecting only antibodies capable of platelet activation. The test measures platelet serotonin release when patient serum is incubated with donor platelets in the presence of heparin. Results are available within 24-48 hours but require special expertise and equipment, limiting availability. Flow cytometry and other newer functional assays are emerging alternatives.

Integration of serologic and functional testing: For high 4Ts probability patients with positive ELISA, the diagnosis is HIT. For intermediate 4Ts probability, if ELISA is positive, functional assay (SRA or HIA) is recommended to confirm clinically significant antibodies. For low 4Ts probability, negative ELISA reliably excludes HIT; positive ELISA is usually a false positive. Some centers use reflex testing: ELISA first, with functional assay performed only if ELISA is positive, or for intermediate-probability patients.

The diagnosis of HIT requires BOTH clinical features AND serologic evidence. Clinical features include: thrombocytopenia (platelet count

Refractory/special situations: high-dose IVIG blocks FcγRIIa and is used for severe or autoimmune HIT; therapeutic plasma exchange can lower antibody titer before urgent cardiopulmonary bypass. Elective cardiac surgery is ideally deferred until functional assays are negative, when intraoperative heparin may be re-used as a single exposure.

Contraindicated/avoid: any heparin re-exposure, LMWH substitution (80–90% antibody cross-reactivity), prophylactic platelet transfusion, and routine IVC filter placement (ASH advises against both in acute HIT).